Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Cash (2022 - 2025)

Historic Change in Cash for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $22.3 million.

  • Axsome Therapeutics' Change in Cash rose 9048.27% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 9768.11%. This contributed to the annual value of -$70.8 million for FY2024, which is 13821.94% down from last year.
  • Axsome Therapeutics' Change in Cash amounted to $22.3 million in Q3 2025, which was up 9048.27% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Change in Cash peaked at $190.6 million during Q2 2023, and registered a low of -$54.8 million during Q1 2024.
  • Its 4-year average for Change in Cash is $15.9 million, with a median of -$11.3 million in 2022.
  • Per our database at Business Quant, Axsome Therapeutics' Change in Cash soared by 268770.54% in 2023 and then crashed by 21987.83% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Change in Cash (Quarter) stood at -$26.7 million in 2022, then decreased by 13.84% to -$30.4 million in 2023, then surged by 60.53% to -$12.0 million in 2024, then soared by 285.65% to $22.3 million in 2025.
  • Its Change in Cash was $22.3 million in Q3 2025, compared to $2.1 million in Q2 2025 and -$14.4 million in Q1 2025.